Results 131 to 140 of about 57,366 (267)

Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants. [PDF]

open access: yesNat Commun
Wang M   +23 more
europepmc   +1 more source

Prelacrimal Transmaxillary‐Orbital Approach for Resection of Lateral Extraconal Orbital Cavernous Hemangioma

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Endoscopic orbital surgery is likely a reasonable option for patients with orbital cavernous hemangiomas (OCH) medial to the optic nerve (ON). The endoscopic resection of OCH lateral to the ON is extremely challenging. Zhou et al. first described the endoscopic prelacrimal recess approach (PLRA) for the management of the maxillary sinus and ...
Zhen‐Xiao Huang   +2 more
wiley   +1 more source

Hormone Replacement Therapy Uptake and Discontinuation Trends From 1996‐2023: An Observational Study of the Welsh Population

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To analyse prescribing trends for oral and transdermal hormone replacement therapy (HRT) in Wales from 1996 to 2023, including predictors of discontinuation within one year of initiation. Design Observational study using the Secure Anonymised Information Linkage (SAIL) databank.
Robin Andrews   +3 more
wiley   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian   +3 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

open access: yesAddiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden   +10 more
wiley   +1 more source

Interstitial granulomatous drug reaction after intranasal desmopressin administration

open access: yesIndian Journal of Dermatology, 2016
Maione, Vincenzo   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy